Background: Monocyte chemoattractant protein-1 (MCP-1) is a member of the CC
chemokine family that plays a key role in the inflammatory process. It has been broadly studied
in the aspect of its role in obesity and diabetes related diseases. MCP-1 causes the infiltration
of macrophages into obese adipose tissue via binding to the CCR2 receptor and is involved
in the development of insulin resistance.
Methods: We reviewed the available literature regarding the importance of plant metabolites
that regulate MCP-1 activity and are used in the treatment of diabetic disorders. The characteristics
of screened papers were described and the important findings were included in this review.
Results: This mini-review provides a summary of functions and therapeutic strategies of this
chemokine, with a special focus on plant-derived compounds that possess a putative antidiabetic
function via a mechanism of MCP-1 interaction. The highlights of this review include the
roles of MCP-1 in development of diabetes, the evaluation of plant metabolites that specifically
or non-specifically inhibit MCP-1 overproduction, and the molecular mechanisms of this
activity. Among these metabolites, we particularly focused on phenolic acids and their derivatives,
flavonoids, stilbenes, anthocyanins, capsaicin, alkaloids, plant sterols, terpenes, saponins,
unsaturated fatty acids and plant-derived extracts.
Conclusion: Regarding the increasing number of diabetic patients yearly, the recent progress
in the putative therapies needs to be summarized. This article underlines the significance and
involvement of the chemokine MCP-1 in the development of obesity, type 2 diabetes, and diabetic
complications, with an emphasis on the role of plant metabolites in the regulation of this
chemokine and thus the role in the prevention or therapy of diabetes. We suggest that MCP-1
might be a molecular marker of type 2 diabetes.